Research programme: zinc finger protein antagonists - Achillion

Drug Profile

Research programme: zinc finger protein antagonists - Achillion

Alternative Names: ACH 100703; ACH 10076

Latest Information Update: 01 Apr 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Achillion Pharmaceuticals
  • Developer Achillion Pharmaceuticals; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases
  • Class
  • Mechanism of Action HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 07 Oct 2002 Data presented at the 42nd Annual Meeting of the Interscience Conference on Anitmicrobial Agents and Chemotherapy (ICAAC-2002) have been added to the Viral Infections antimicrobial activity and pharmacodynamics sections
  • 13 Jul 2001 Preclinical development for HIV infections treatment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top